The company plans to manufacture reference standards for distribution to their research and forensics customers.

In reference to drug codes 7360 (marihuana) and 7370 (tetrahydrocannabinols), the company plans to bulk manufacture these drugs as synthetic. No other activities for these drug codes are authorized for this registration.

---

**Controlled substance** | **Schedule**
--- | ---
2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxy-benzyl)ethanamine (25C-NBOMe) | I
2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe) | I
Methyloclyone (3,4-Methylendioxy-N-methylcathinone) | I
Butylone (7541) | I
Pentylone (7542) | I
alpha-pyralidinopentophenone (α-PVP) | I
alpha-pyrrolidinobutylphenone (α-PBP) | I
AM–694 | I
Acetyldihydrocodeine (9051) | I
Benzylmorphine (9052) | I
Codeine-N-oxide (9053) | I
Desomorphine (9055) | I
Dihydromorphine (9145) | I
Heroin (9200) | I
Morphine-N-oxide (9307) | I
Normorphone (9313) | I
Tilidine (9750) | I
Acetyl Fentanyl (N-(1-phenethylpyrrolidin-4-yl)-N-phenylacetamide) | I
Amphetamine (1100) | II
Methamphetamine (1105) | II
Lisdexamfetamine (1205) | II
Methylphenidate (1724) | II
Amobarbital (2125) | II
Pentobarbital (2270) | II
Secobarbital (2315) | II
Phencyclidine (7471) | I
Phencyclidone (7471) | I
Phenacetine (8501) | II
Cocaine (9041) | II
Codeine (9050) | II
Dihydrocodeine (9120) | II
Oxycodone (9143) | II
Hydromorphone (9150) | II
Ergonine (9180) | II
Ethylmorphine (9190) | II
Hydrocodone (9193) | II
Levomethorphan (9210) | II
Levorphanol (9220) | II
Meperidine (9230) | II
Meperidine intermediate-B (9233) | II
Methadone (9250) | II
Dextropropoxyphene, bulk | I
Morphine (9300) | II
Thebaine (9333) | II
Oxymorphone (9652) | II
Sufentanyl (9740) | II
Tapentadol (9870) | II
Fentanyl (9801) | II

---

**Controlled substance** | **Schedule**
--- | ---
Tapentadol (9780) | II
Oxymorphone (9652) | II

---

The company plans to bulk manufacture the above-listed controlled substances in bulk for distribution to its customers.

**DEPARTMENT OF JUSTICE**

Drug Enforcement Administration

[Docket No. DEA–392]

Bulk Manufacturer of Controlled Substances Application: Janssen Pharmaceutical, Inc.

**ACTION:** Notice of application.

**DATES:** Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration in accordance with 21 CFR 1301.33(a) on or before April 25, 2016

**ADDRESSES:** Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/ODW, 8701 Morrissette Drive, Springfield, Virginia 22152.

**SUPPLEMENTARY INFORMATION:** The Attorney General has delegated her authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA). 28 CFR 0.100(h). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers, importers, and exporters of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Deputy Assistant Administrator of the DEA Office of Diversion Control (“Deputy Assistant Administrator”) pursuant to section 7 of 28 CFR part 0, appendix to subpart R.

In accordance with 21 CFR 1301.33(a), this is notice that on November 12, 2015, Janssen Pharmaceutical, Inc., 1440 Olympic Drive, Athens, Georgia 30601 applied to be registered as a bulk manufacturer of the following basic classes of controlled substances:

<table>
<thead>
<tr>
<th>Controlled substance</th>
<th>Schedule</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methylnenadate (1724)</td>
<td>II</td>
</tr>
<tr>
<td>Oxycodone (9143)</td>
<td>II</td>
</tr>
<tr>
<td>Hydromorphone (9150)</td>
<td>II</td>
</tr>
<tr>
<td>Hydrocodone (9193)</td>
<td>II</td>
</tr>
<tr>
<td>Oripavine (9330)</td>
<td>II</td>
</tr>
<tr>
<td>Thebaine (9333)</td>
<td>II</td>
</tr>
<tr>
<td>Oxymorphone (9652)</td>
<td>II</td>
</tr>
</tbody>
</table>

**DEPARTMENT OF JUSTICE**

Drug Enforcement Administration

[Docket No. DEA–392]

Manufacturer of Controlled Substances Registration: Cedarburg Pharmaceuticals, Inc.

**ACTION:** Notice of registration.

**SUMMARY:** Cedarburg Pharmaceuticals, Inc. applied to be registered as a manufacturer of certain basic classes of controlled substances. The Drug Enforcement Administration (DEA) grants Cedarburg Pharmaceuticals, Inc. registration as a manufacturer of those controlled substances.

**SUPPLEMENTARY INFORMATION:** By notice dated September 16, 2015, and published in the Federal Register on September 23, 2015, 80 FR 57390, Cedarburg Pharmaceuticals, Inc., 870 Badger Circle, Grafton, Wisconsin 53024 applied to be registered as a manufacturer of certain basic classes of controlled substances. No comments or objections were submitted for this notice.

The DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Cedarburg Pharmaceuticals, Inc. to manufacture the basic classes of controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. The DEA investigated the company’s maintenance of effective controls against diversion by inspecting and testing the company’s physical security systems, verifying the company’s compliance with state and local laws, and reviewing the company’s background and history.

Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the above-named company is granted registration as a bulk manufacturer of the following basic classes of controlled substances: